1
|
Dockrell DH, O’Shea D, Cartledge JD, Freedman AR. British HIV Association guidelines on the management of opportunistic infection in people living with HIV: The clinical management of Candidiasis 2019. HIV Med 2020; 20 Suppl 8:2-24. [PMID: 31670458 DOI: 10.1111/hiv.12806] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- D H Dockrell
- University of Edinburgh, Edinburgh, UK and Regional Infectious Diseases Unit, NHS Lothian Infection Service, Edinburgh, UK
| | - D O’Shea
- University of Edinburgh, Edinburgh, UK and Regional Infectious Diseases Unit, NHS Lothian Infection Service, Edinburgh, UK
| | | | - A R Freedman
- Cardiff University School of Medicine, Cardiff, UK
| |
Collapse
|
2
|
Haddow LJ, Accoroni A, Cartledge JD, Manji H, Benn P, Gilson RJC. Routine detection and management of neurocognitive impairment in HIV-positive patients in a UK centre. Int J STD AIDS 2013; 24:217-9. [PMID: 23535355 PMCID: PMC4138002 DOI: 10.1177/0956462412472452] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
We estimated the burden of HIV-associated neurocognitive disorders (HAND) in a UK clinic. From a random sample, and referrals to specialist services over one year (neurology, clinical psychology, hospital admissions), we determined whether patients were diagnosed with HIV-associated dementia (HAD) and whether they reported symptoms suggesting neurocognitive impairment (NCI). In the first sample, 2/150 (prevalence 1.3%; 95% confidence interval [CI] 0.2–4.7%) had documented HAD. Eleven patients (7.3%; CI 3.7–12.7%) reported recent symptoms suggesting NCI; most of these individuals were diagnosed with a psychiatric or substance-use disorder. Among specialist referrals with symptoms suggesting NCI, 11 were diagnosed with HAD from a clinic population of 3129 individuals (annual incidence 0.4%; CI 0.2–0.6%). No patients with mildly symptomatic or asymptomatic HAND were identified in either sample, suggesting that such patients remain undetected in current clinical practice. Evidence-based screening for HAND in HIV clinics may be needed.
Collapse
Affiliation(s)
- L J Haddow
- Centre for Sexual Health and HIV Research, Research Department of Infection and Population Health, University College London
| | | | | | | | | | | |
Collapse
|
3
|
Sayer RA, Whitehorn J, Cartledge JD, Shipley M, Noursadeghi M. An unusual cause of fever in an HIV-positive patient. Int J STD AIDS 2012; 23:453-4. [DOI: 10.1258/ijsa.2009.009375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Patients with HIV frequently present with fever. However, the spectrum of diseases affecting patients with HIV has changed in the era of antiretroviral therapy (ART). Here we present a patient who has an unusual cause for his fever with an eventual diagnosis of adult-onset Still's disease.
Collapse
Affiliation(s)
- R A Sayer
- The Mortimer Market Centre, Camden Provider Services PCT
- University College Hospitals NHS Foundation Trust
| | - J Whitehorn
- University College Hospitals NHS Foundation Trust
| | - J D Cartledge
- The Mortimer Market Centre, Camden Provider Services PCT
| | - M Shipley
- University College Hospitals NHS Foundation Trust
| | - M Noursadeghi
- University College Hospitals NHS Foundation Trust
- Infection and Immunity, University College London, London, UK
| |
Collapse
|
4
|
Abstract
The British HIV Association (BHIVA) recommends that specialist clinical networks are involved in care of HIV-positive patients admitted to district general hospitals (DGHs) and that transfer to a specialist HIV treatment centre is considered for each patient. We audited our experience of 29 patients transferred to our specialist inpatient unit over a two year period. Fifteen (52%) patients were known to be HIV-infected before admission to the referring hospital. Ten (71%) of 14 patients with newly diagnosed HIV had an opportunistic infection at transfer. At the referring hospital the time taken to diagnose HIV infection ranged from one to 26 days (median = 3.5). Only five patients (17%) were transferred by 72 hours of admission to the referring hospital. The duration of stay at our centre was 1–212 days (median = 15): seven patients (24%) required admission to the intensive care unit. Seven patients died; of these, three had newly diagnosed HIV infection. This audit demonstrates that sick HIV-infected patients transferred to a specialist HIV unit had a poor outcome and lengthy hospital admissions. Our audit supports roll-out of HIV testing to avoid adverse outcomes associated with late diagnosis and development of clinical networks involving specialist HIV treatment centres in order to support provision of HIV care in DGHs.
Collapse
Affiliation(s)
| | - S G Edwards
- University College London Hospitals
- Mortimer Market Centre, Camden Provider Services PCT
| | - J D Cartledge
- University College London Hospitals
- Mortimer Market Centre, Camden Provider Services PCT
| | - R F Miller
- University College London Hospitals
- Mortimer Market Centre, Camden Provider Services PCT
- Centre for Sexual Health and HIV Research, University College London, London, UK
| |
Collapse
|
5
|
Wilson AJ, Sayer RA, Edwards SG, Cartledge JD, Miller RF. A comparison of computed tomography and magnetic resonance brain imaging in HIV-positive patients with neurological symptoms. Int J STD AIDS 2010; 21:198-201. [DOI: 10.1258/ijsa.2009.009323] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
We reviewed our practice in order to determine the optimum neuroimaging strategy for HIV-infected patients with acute neurological presentations between April 2007 and August 2008. Overall magnetic resonance imaging (MRI) detected cranial abnormalities in more than twice as many patients as did computed tomography (CT) (74% and 32%, n = 54 and 38, respectively). Replacement of CT by first-line MRI for all patients would have required an additional 16 MRI scans, although at a saving of 38 CT scans. Our study highlights the importance of first-line MRI brain imaging in HIV patients with neurological symptoms and reinforces the need for early transfer of patients from centres that do not have rapid access to (or expert interpretation of) MRI scanning, to an appropriate HIV specialist centre.
Collapse
Affiliation(s)
- A J Wilson
- T8, University College London Hospitals, London NW1 8BU
- Centre for Sexual Health and HIV Research, University College London, London WC1E 6JB
| | - R A Sayer
- T8, University College London Hospitals, London NW1 8BU
- Mortimer Market Centre, Camden Provider Services PCT, London WC1E 6JB, UK
| | - S G Edwards
- T8, University College London Hospitals, London NW1 8BU
- Mortimer Market Centre, Camden Provider Services PCT, London WC1E 6JB, UK
| | - J D Cartledge
- T8, University College London Hospitals, London NW1 8BU
- Mortimer Market Centre, Camden Provider Services PCT, London WC1E 6JB, UK
| | - R F Miller
- T8, University College London Hospitals, London NW1 8BU
- Centre for Sexual Health and HIV Research, University College London, London WC1E 6JB
| |
Collapse
|
6
|
Abstract
A retrospective case-notes audit of 359 HIV-1-infected adult patients with first-episode laboratory-confirmed Pneumocystis jirovecii pneumonia treated with co-trimoxazole (from 1987 adjuvant steroids were used if PaO2 <9.3 kPa) showed that only 230/359 (64%) patients completed treatment; 104 (29%) patients had treatment-limiting toxicity; rash occurred in 4/60 (6.7%) patients in 1985–1988 and in 15/47 (31.9%) in 2005–2008. Twenty-five patients (7%) failed co-trimoxazole treatment. Overall mortality was 13.6% (49/359); mortality among patients who failed co-trimoxazole treatment was 48% (12/25) and by contrast mortality was 4.8% (5/104) among patients with treatment-limiting toxicity.
Collapse
Affiliation(s)
- M Fisk
- Department of Genitourinary Medicine, Camden Provider Services PCT, Mortimer Market Centre, London WC1E 6JB
- T8, University College London Hospitals, London NW1 8BU
| | - E K Sage
- T8, University College London Hospitals, London NW1 8BU
| | - S G Edwards
- Department of Genitourinary Medicine, Camden Provider Services PCT, Mortimer Market Centre, London WC1E 6JB
| | - J D Cartledge
- Department of Genitourinary Medicine, Camden Provider Services PCT, Mortimer Market Centre, London WC1E 6JB
- T8, University College London Hospitals, London NW1 8BU
| | - R F Miller
- T8, University College London Hospitals, London NW1 8BU
- Department of Infection and Population Health, University College London Medical School, University College London, London W1E 6JB, UK
| |
Collapse
|
7
|
Abstract
Sexually transmitted infection (STI) rates among men having sex with men continue to increase. HIV services may operate independently to genitourinary medicine clinics and the sexual health of HIV-positive patients may be of low priority in the context of medical problems related to HIV. A prospective study of HIV-positive gay men was conducted in a London outpatient clinic over a three-month period. Data were available for 90 men. Forty-five percent had STI screens in the preceding six months. These revealed a high rate of infections; 26 infections diagnosed in 14 men in the study period. Fifty-seven percent of the 90 men in the study had more than one partner in the past three months and approximately one-third had unprotected sexual activity. A significant proportion of men were unaware of recent outbreaks of hepatitis C and lymphogranuloma venereum and of HIV postexposure prophylaxis. We therefore recommend that sexual history-taking, STI screens and health promotion should become a routine feature of HIV outpatient consultations in this group.
Collapse
Affiliation(s)
- R A Ferrand
- Department of Genitourinary Medicine, Mortimer Market Centre and Archway Sexual Health Centre, Camden Primary Care Trust, London
| | - S De Silva
- Department of Genitourinary Medicine, Mortimer Market Centre and Archway Sexual Health Centre, Camden Primary Care Trust, London
| | - J D Cartledge
- Department of Genitourinary Medicine, Mortimer Market Centre and Archway Sexual Health Centre, Camden Primary Care Trust, London
| |
Collapse
|
8
|
Ferrand RA, Cartledge JD, Connolly J, Standish RA, Miller RF. Immune reconstitution sarcoidosis presenting with hypercalcaemia and renal failure in HIV infection. Int J STD AIDS 2007; 18:138-9. [PMID: 17331293 DOI: 10.1258/095646207779949574] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
An HIV-positive white man developed hypercalcaemia and renal failure 15 months after starting highly active antiretroviral therapy. Investigations showed systemic sarcoidosis affecting parotids, skin and kidneys. This presentation was thought to be a manifestation of immune reconstitution inflammatory syndrome, and the patient was successfully treated with corticosteroid therapy.
Collapse
Affiliation(s)
- R A Ferrand
- University College London Hospitals, London NW1 2BU, UK; Camden Primary Care Trust, Mortimer Market Centre, London WC1E 6AU, UK
| | | | | | | | | |
Collapse
|
9
|
Brown M, Cartledge JD, Miller RF. Dissemination of Strongyloides stercoralis as an immune restoration phenomenon in an HIV-1-infected man on antiretroviral therapy. Int J STD AIDS 2006; 17:560-1. [PMID: 16925906 DOI: 10.1258/095646206778145712] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
We present a case of Strongyloides stercoralis infection in an HIV-infected man, resulting in Escherichia coli meningitis after initiation of antiretroviral therapy. Recent evidence from studies of strongyloides development supports the concept that strongyloides dissemination in this case is an example of an immune reconstitution inflammatory syndrome.
Collapse
Affiliation(s)
- M Brown
- Patrick Manson Unit, University College London Hospitals, London, UK.
| | | | | |
Collapse
|
10
|
Dave SS, Noursadeghi M, Rickards D, Cartledge JD, Miller RF. Atypical presentation of lobar nephronia in an adult co-infected with HIV and hepatitis C. Sex Transm Infect 2005; 81:183. [PMID: 15800106 PMCID: PMC1764677 DOI: 10.1136/sti.2004.011759] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
11
|
Hillier JC, Shaw P, Miller RF, Cartledge JD, Nelson M, Bower M, Francis N, Padley SP. Imaging features of multicentric Castleman's disease in HIV infection. Clin Radiol 2004; 59:596-601. [PMID: 15208065 DOI: 10.1016/j.crad.2003.10.025] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2003] [Revised: 10/15/2003] [Accepted: 10/22/2003] [Indexed: 12/11/2022]
Abstract
AIM To describe the computed tomography (CT) features of human immunodeficiency virus (HIV)-associated Castleman's disease. MATERIALS AND METHODS Nine HIV-positive patients with biopsy-proven Castleman's disease were studied. Clinical and demographic data, CD4 count, histological diagnosis and human herpes type 8 (HHV8) serology or immunostaining results were recorded. CT images were reviewed independently by two radiologists. RESULTS CT findings included splenomegaly (n=7) and peripheral lymph node enlargement (axillary n=8, inguinal n=4). All nodes displayed mild to avid enhancement after intravenous administration of contrast material. Hepatomegaly was evident in seven patients. Other features included abdominal (n=6) and mediastinal (n=5) lymph node enlargement and pulmonary abnormalities (n=4). Patterns of parenchymal abnormality included bronchovascular nodularity (n=2) consolidation (n=1) and pleural effusion (n=2). On histological examination eight patients (spleen n=3, lymph node n=9, lung n=1, bone marrow n=1) had the plasma cell variant and one had mixed hyaline-vascular/plasma cell variant. The majority had either positive immunostaining for HHV8 or positive serology (n=8). CONCLUSION Common imaging features of multicentric Castleman's disease in HIV infection are hepatosplenomegaly and peripheral lymph node enlargement. Although these imaging features may suggest the diagnosis in the appropriate clinical context, they lack specificity and so biopsy is needed for diagnosis. In distinction from multicentric Castleman's disease in other populations the plasma cell variant is most commonly encountered, splenomegaly is a universal feature and there is a strong association with Kaposi's sarcoma.
Collapse
Affiliation(s)
- J C Hillier
- Clinical Radiology, Chelsea and Westminster Hospital, London, UK.
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Buckley J, Shaw PJ, Cartledge JD, Miller RF. Multicentric plasma cell variant Castleman's disease mimicking intrapulmonary malignancy. Sex Transm Infect 2002; 78:304-5. [PMID: 12181475 PMCID: PMC1744519 DOI: 10.1136/sti.78.4.304] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Affiliation(s)
- J Buckley
- Department of Sexually Transmitted Diseases, Royal Free and University College Medical School, Camden and Islington Community Health Services NHS Trust, Mortimer Market Centre, London, UK
| | | | | | | |
Collapse
|
13
|
Affiliation(s)
- J D Cartledge
- Royal Free & University College Medical School, Mortimer Market Centre, London, UK
| |
Collapse
|
14
|
Smith A, Cartledge JD, Griffiths MH, Miller RF. Response of hepatitis B induced membranoproliferative glomerulonephritis to HAART. Sex Transm Infect 2001; 77:302-3. [PMID: 11463942 PMCID: PMC1744336 DOI: 10.1136/sti.77.4.302-b] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
15
|
Abstract
Specimens from HIV-positive patients with oral candidosis were taken for culture, species identification and azole susceptibility testing, which was correlated with treatment outcome. Of 921 specimens, 95 yielded non-albicans species, mainly from patients with low CD4 lymphocyte counts and extensive previous azole exposure. Most non-albicans isolates were from specimens co-infected with Candida albicans, complicating the interpretation of in-vitro susceptibility results, which accurately predicted antifungal failure when the non-albicans species was isolated alone. Eighty-five non-albicans isolates were resistant to fluconazole in vitro. Of 149 courses of azole therapy prescribed, 115 failed to clear non-albicans candidosis clinically. Culture media that discoloured in the presence of non-albicans colonies might, therefore, guide therapy.
Collapse
Affiliation(s)
- J D Cartledge
- Department of HIV and Genitourinary Medicine, St Stephen's Centre, Chelsea and Westminster Hospital, London, UK
| | | | | |
Collapse
|
16
|
Cartledge JD, Midgley J, Gazzard BG. Transmission of fluconazole-resistant Candida strains between HIV-positive patients and their sexual partners. AIDS 1998; 12:1249-51. [PMID: 9677179 DOI: 10.1097/00002030-199810000-00022] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
17
|
Cartledge JD, Denning DW, Dupont B, Clumeck N, De Wit S, Midgley J, Hawkins DA, Gazzard BG. Treatment of HIV-related fluconazole-resistant oral candidosis with D0870, a new triazole antifungal. AIDS 1998; 12:411-6. [PMID: 9520171 DOI: 10.1097/00002030-199804000-00010] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
OBJECTIVES To evaluate the efficacy and tolerance of D0870 in the treatment of HIV-related fluconazole-resistant oro-oesophageal candidosis. DESIGN Multicentre open study. PATIENTS HIV-seropositive patients with oro-oesophageal candidosis despite at least 7 days of treatment with fluconazole at doses of 100 mg per day or more. METHODS Patients received an initial dose of D0870 (150 mg), then 25 mg per day for 6 days. Symptoms and signs of candidosis were compared at entry and on days 3 and 7 of treatment. At each visit, samples were taken for safety monitoring and for in vitro susceptibility testing of Candida isolates. Limited pharmacokinetic samples were taken on days 1 and 7. RESULTS Of 26 evaluable patients, 16 showed partial improvement, nine showed no improvement, and only one had full clearance of thrush by day 7. In vitro testing of the cleared patient's isolate suggested that it was susceptible to fluconazole. Symptoms of dysphagia cleared in 14 and improved in five of the 22 patients with presumptive oesophageal involvement at entry. Pharmacokinetic measurement showed wide variability in maximum D0870 levels recorded on day 1 (range, 0.07-0.34 mg/l) and susceptibility testing of isolates also showed a range of minimal inhibitory concentration values to D0870 (range, < 0.06-8 mg/l; median, 0.25 mg/l). When these data were combined with clinical response there was a strong suggestion that lack of symptomatic improvement was related to low plasma D0870 levels or to the presence of less D0870-susceptible isolates. Six patients were noted to have a fall in haemoglobin, three of whom were receiving concomitant therapy known to suppress bone marrow. Three patients reported headaches as adverse events that were attributed to study medication, but D0870 was well tolerated overall. CONCLUSIONS D0870 shows promise in the treatment of fluconazole-resistant oro-oesophageal candidosis and was well tolerated, although efficacy in this difficult-to-treat patient group was probably limited due to the inadequate plasma levels achieved in this pilot study with the low doses of D0870 administered.
Collapse
|
18
|
Cartledge JD, Weller IV. Shared care in HIV and AIDS: shifting care or shifting costs? J R Coll Physicians Lond 1998; 32:376-9. [PMID: 9762635 PMCID: PMC9663086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/05/2022]
Affiliation(s)
- J D Cartledge
- Department of Genitourinary Medicine, Camden and Islington Community Health Services, London
| | | |
Collapse
|
19
|
Abstract
OBJECTIVES To determine the proportion of fluconazole-resistant Candida albicans isolates that have clinically significant cross-resistance to itraconazole or ketoconazole, that is sufficient to result in failure of these agents at their standard doses (200 and 400 mg daily for 7 days, respectively). METHODS Seven hundred C. albicans isolates from HIV-positive patients with oral candidosis underwent susceptibility testing using a relative growth method, for which cut-off values corresponding to clinical drug failure have been established. RESULTS A total of 431 isolates were fully azole-susceptible and three main resistance patterns were detected: isolates resistant to fluconazole alone (n = 100); isolates resistant to fluconazole and ketoconazole but susceptible to itraconazole (n = 94); and isolates resistant to all three drugs (n = 50). No isolates were consistently resistant to ketoconazole without being fluconazole-resistant, and no itraconazole resistance was detected without ketoconazole resistance. Resistance to fluconazole alone was more common in specimens obtained soon after first clinical fluconazole failure, whereas specimens from patients with a longer history of fluconazole-unresponsive candidosis were more likely to be infected with cross-resistant isolates. Median days of prior azole exposure and cumulative fluconazole dose were significantly less for those with isolates resistant to fluconazole alone than for those with ketoconazole cross-resistant isolates, who had received less azole therapy and smaller cumulative fluconazole doses than those with isolates cross-resistant to all three drugs (although not statistically significant). After the diagnosis of fluconazole-unresponsive candidosis, increasing cumulative doses of itraconazole solution were associated with increasing likelihood of cross-resistance. CONCLUSIONS Clinically significant cross-resistance to other azoles may occur in fluconazole-resistant isolates of C. albicans, although initially most isolates are not cross-resistant and the detection of cross-resistant isolates is associated with a history of greater prior azole exposure. Patients who have been treated for fluconazole-resistant candidosis for longer and with greater cumulative doses of itraconazole solution tend to become infected with increasingly cross-resistant isolates of C. albicans.
Collapse
Affiliation(s)
- J D Cartledge
- Department of HIV/GU Medicine, St Stephen's Centre, Chelsea and Westminster Hospital, London, UK
| | | | | |
Collapse
|
20
|
Cartledge JD, Midgley J, Gazzard BG. Prior fluconazole exposure as an independent risk factor for fluconazole resistant candidosis in HIV positive patients: a case-control study. Genitourin Med 1997; 73:471-4. [PMID: 9582463 PMCID: PMC1195927 DOI: 10.1136/sti.73.6.471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
OBJECTIVES To determine if prior fluconazole exposure was an independent risk factor for fluconazole resistant candidosis in HIV positive patients. METHODS Twenty five HIV positive cases with fluconazole resistant oral candidosis were matched by CD4 lymphocyte count and time since first episode of candidosis to 25 HIV positive controls with susceptible candidosis. For each individual a history of prior azole prophylaxis was compiled from computerised pharmacy records and review of case notes. RESULTS The total days of prior azole therapy prescribed was significantly greater for cases than controls. These differences were attributable to prescriptions for secondary prophylaxis against recurrent candidosis, the cases having received significantly longer continuous azole prophylaxis than controls, with no difference in days of prior azole therapy remaining between the two groups if prophylactic prescriptions were excluded. The total cumulative dose of fluconazole received was significantly higher for cases than controls, though mean daily fluconazole doses did not differ significantly between the two groups. CONCLUSION Even after controlling for degree of immunosuppression and duration of recurrent candidosis, the association between prior azole exposure and fluconazole resistant candidosis remains significant and largely reflects differences in the prescription of secondary antifungal prophylaxis.
Collapse
Affiliation(s)
- J D Cartledge
- Department of HIV and GU Medicine, Chelsea and Westminster Health Care Trust, London
| | | | | |
Collapse
|
21
|
Cartledge JD, Midgley J, Petrou M, Shanson D, Gazzard BG. Unresponsive HIV-related oro-oesophageal candidosis--an evaluation of two new in-vitro azole susceptibility tests. J Antimicrob Chemother 1997; 40:517-23. [PMID: 9372421 DOI: 10.1093/jac/40.4.517] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Azole-resistant HIV-related candidosis is increasingly recognized. We evaluated two new in-vitro susceptibility tests (the NCCLS proposed MIC method and Odds' assessment of relative growth in single anti-fungal concentration) as predictors of the clinical outcome of 66 HIV-positive patients with oral candidosis, of whom 22 were azole naive, 27 had always previously responded to azole therapy and 17 had persistent candidosis unresponsive to 7 days of standard azole therapy. None of the last group responded to increased daily doses of fluconazole or itraconazole capsules, though nine responded to itraconazole cyclodextrin solution 200 mg bd for 7 days. Our findings suggest that agreement between the Odds' test and the MIC method was excellent (96-98%) and that both could discriminate between isolates of azole-unresponsive patients and those of azole-responsive patients. For fluconazole susceptibility an MIC > or = 8 mg/L detected fluconazole-unresponsive patients with a sensitivity of 94% and specificity of 100%; Odds' method achieved 100% sensitivity and 100% specificity using all cut-offs between 77 and 88% relative growth in medium containing fluconazole (10(-5) M; 3 mg/L). For itraconazole and ketoconazole agreement between MIC and Odds' method was again excellent (98% and 96%, respectively) but five azole-unresponsive patients appeared to have ketoconazole-susceptible organisms as defined by both tests, and similarly 11 appeared to have itraconazole-susceptible organisms by both tests despite failing to respond to the capsule formulation of the drug. Of these 11, eight responded to itraconazole solution; this finding implies that itraconazole capsule failure might represent poor drug absorption rather than fungal resistance.
Collapse
Affiliation(s)
- J D Cartledge
- HIV/GU Medicine Unit, Chelsea & Westminster Hospital, London, UK
| | | | | | | | | |
Collapse
|
22
|
Cartledge JD, Midgley J, Gazzard BG. Clinical response to ketoconazole of HIV-related oral candidosis is predicted by Odds' relative growth method of susceptibility testing. J Antimicrob Chemother 1997; 40:117-9. [PMID: 9249214 DOI: 10.1093/jac/40.1.117] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
In-vitro ketoconazole susceptibility was assessed by measuring an isolate's relative growth in medium containing a fixed concentration of ketoconazole as a percentage of growth in drug-free medium. One hundred specimens from HIV-positive patients with candidosis were tested. Each patient's response was assessed following one week's treatment with ketoconazole 400 mg/day. A relative growth in ketoconazole of >75% predicted clinical failure of ketoconazole with a specificity of 97% and sensitivity of 79%.
Collapse
Affiliation(s)
- J D Cartledge
- Department of HIV & Genito-Urinary Medicine, St Stephen's Centre, Chelsea & Westminster Healthcare NHS Trust, London, UK
| | | | | |
Collapse
|
23
|
Cartledge JD, Midgely J, Gazzard BG. Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis. J Clin Pathol 1997; 50:477-80. [PMID: 9378812 PMCID: PMC499974 DOI: 10.1136/jcp.50.6.477] [Citation(s) in RCA: 96] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
AIMS To compare the serum concentrations of itraconazole and hydroxyitraconazole after treatment with itraconazole cyclodextrin solution and itraconazole capsules in human immunodeficiency virus (HIV) positive patients with oral candidosis. METHODS The pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole were assessed on days 1 and 7 of therapy in acquired immunodeficiency syndrome (AIDS) patients with oral candidosis taking either itraconazole solution or capsules and the serum concentrations (measured by high performance liquid chromatography) correlated with the clinical response to therapy. In addition, the in vitro susceptibility of Candida spp isolates taken from patients at the start of the therapy was assessed. RESULTS Nine of 16 patients treated with itraconazole capsules and eight of 15 treated with the solution responded to treatment. Three of the non-responders in each treatment group were infected with isolates resistant to itraconazole in vitro. Although with both preparations there was considerable inter-patient variability in the maximum recorded serum concentrations of itraconazole, they were significantly lower on day 1 and day 7 in those receiving capsules compared with those taking the solution. Patients unresponsive to therapy, but infected with susceptible isolates, had significantly lower concentrations of itraconazole and hydroxyitraconazole levels on days 1 and 7 than patients responding to treatment. However, patients infected with itraconazole resistant isolates (tested in vitro) failed to respond to treatment despite achieving similar serum concentrations of itraconazole and hydroxy-itraconazole to the responsive patients. For patients with in vitro susceptible isolates a serum itraconazole concentration of < 1000 ng/ml on day 7 was predictive of therapeutic failure (specificity 71%, sensitivity 100%). CONCLUSIONS Itraconazole cyclodextrin solution achieves higher serum itraconazole and hydroxy-itraconazole concentrations than the capsule formulation in AIDS patients, and this is associated with improved efficacy.
Collapse
Affiliation(s)
- J D Cartledge
- St Stephen's Centre, Chelsea and Westminster Hospital, London, UK
| | | | | |
Collapse
|
24
|
De Wit S, Dupont B, Cartledge JD, Hawkins DA, Gazzard BG, Clumeck N, Denning DW. A dose comparison study of a new triazole antifungal (D0870) in HIV-positive patients with oral candidiasis. AIDS 1997; 11:759-63. [PMID: 9143608 DOI: 10.1097/00002030-199706000-00009] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
OBJECTIVE This multicentre study evaluated the clinical efficacy and tolerability of D0870 in treating oropharyngeal candidiasis in HIV-positive patients who had no history of clinical resistance to fluconazole. METHODS Three regimens were evaluated in two phases. In phase I a 50 mg initial dose was followed by 10 mg for 4 days (Group 1). In phase II a 100 mg initial dose was followed by 25 mg for 4 days (Group 2), or 10 mg for 5 days (Group 3). RESULTS Clinical cure was obtained in 27 patients of a total of 35 (77%) and six other patients improved (17%). Two patients at the lowest dose failed and both had very low plasma concentration of D0870. No association was found between clinical outcome; minimum inhibitory concentration of D0870 pre-therapy for Candida albicans, maximum recorded plasma D0870 concentration, cfu of culture or CD4 cell count at entry. Overall, 37% of the patients experienced relapse during the 2 weeks post therapy. Tolerance was excellent. Mild adverse events possibly related to the study drug were recorded in five patients. CONCLUSION D0870 demonstrates excellent efficacy at low doses in the treatment of HIV-related OPC and exhibits a favourable safety profile.
Collapse
Affiliation(s)
- S De Wit
- Saint-Pierre Hospital, Brussels, Belgium
| | | | | | | | | | | | | |
Collapse
|
25
|
Cartledge JD, Midgley J, Gazzard BG. Itraconazole cyclodextrin solution: the role of in vitro susceptibility testing in predicting successful treatment of HIV-related fluconazole-resistant and fluconazole-susceptible oral candidosis. AIDS 1997; 11:163-8. [PMID: 9030362 DOI: 10.1097/00002030-199702000-00005] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
OBJECTIVES This study assessed the ability of in vitro susceptibility testing of clinical Candida isolates to predict in vivo response to itraconazole cyclodextrin solution. METHODS One hundred specimens were obtained from HIV-positive patients with oral thrush, of which 72 speciments were from patients who were clinically unresponsive to fluconazole at standard doses and had fluconazole-resistant isolates in vitro. Susceptibility to itraconazole was assessed by measuring the relative growth of an isolate in liquid medium containing a single concentration of itraconazole and then expressing growth in itraconazole as a percentage of growth in antifungal-free medium. RESULTS AND CONCLUSIONS Where specimens yielded only one isolate, a cut-off relative growth in itraconazole of 68% discriminated between isolates from patients failing to respond clinically to itraconazole solution and those from patients successfully treated with the preparation (specificity 100%; sensitivity 88%). The presence of mixed infection reduced the predictive accuracy of the test. Only 30% of fluconazole-resistant isolates were cross-resistant to itraconazole. No isolates were resistant to itraconazole but susceptible to fluconazole. Non-response to itraconazole solution was attributed to resistant yeast infection in the majority of cases, and this susceptibility method accurately identified specimens from patients unlikely to respond to the drug.
Collapse
Affiliation(s)
- J D Cartledge
- Department of HIV & Genito-Urinary Medicine, St Stephen's Centre, Chelsea & Westminster Healthcare NHS Trust, London, UK
| | | | | |
Collapse
|
26
|
Cartledge JD, Midgley J, Gazzard BG. Relative growth measurement of Candida species in a single concentration of fluconazole predicts the clinical response to fluconazole in HIV infected patients with oral candidosis. J Antimicrob Chemother 1996; 37:275-83. [PMID: 8707737 DOI: 10.1093/jac/37.2.275] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
The growth of 113 Candida spp. isolated prospectively from 104 HIV-positive patients treated for thrush was determined using a single concentration of 3 mg/L (10(-5) M) fluconazole relative to growth in drug free medium. Using a receiver operator characteristic curve, a relative growth in fluconazole of > or = 88% best discriminated between isolates from 56 patients who responded to treatment with fluconazole and 48 who failed to respond to 7 days, treatment with at least 100 mg/d drug with a sensitivity of 98% and a specificity of 96%. When the isolates from the eight patients with mixed infections due to both resistant and susceptible yeasts were excluded, the sensitivity and specificity both reached 100%. Relative growth of Candida spp. in a single concentration of fluconazole can therefore be used to accurately predict the clinical response to standard fluconazole treatment of thrush in patients infected with HIV.
Collapse
Affiliation(s)
- J D Cartledge
- Department of HIV/Genito-urinary Medicine, Chelsea & Westminster Health Care Trust, London, UK
| | | | | |
Collapse
|
27
|
Keating JJ, Rogers T, Petrou M, Cartledge JD, Woodrow D, Nelson M, Hawkins DA, Gazzard BG. Management of pulmonary aspergillosis in AIDS: an emerging clinical problem. J Clin Pathol 1994; 47:805-9. [PMID: 7962648 PMCID: PMC494936 DOI: 10.1136/jcp.47.9.805] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
AIMS To review the clinical, radiographic, and therapeutic features of 11 cases of respiratory Aspergillus infection in patients with AIDS. METHODS All induced sputum and bronchoalveolar lavage samples obtained from HIV seropositive patients between January 1985 and March 1993 were analysed for Aspergillus species. Additionally, where appropriate, bronchial or renal biopsy specimens, or both, were taken before treatment had started. RESULTS In 11 patients Aspergillus fumigatus was identified in alveolar samples obtained by sputum induction. This was confirmed by bronchoalveolar lavage in eight. Three patients had Aspergillus plaques in the trachea and bronchus, while a fourth patient had an aspergilloma. Risk factors for Aspergillus infection were present in all patients, including corticosteroid treatment in three cases and neutropenia in four, three of whom had received chemotherapy for Kaposi's sarcoma. Four patients had concomitant cytomegalovirus infection. Ten patients had a CD4 count of less than 50 cells/mm3 while one patient had a disseminated T cell lymphoma with a CD4 count of 242 cells/mm3. Of the three patients with samples obtained by sputum induction who did not undergo bronchoscopy, two had a normal chest x ray picture and the third had a right lobar pneumonia complicating an aggressive lymphoma. All three were treated with itraconazole 200 mg twice a day without further investigation. Survival from the time of diagnosis of Aspergillus infection was short: seven patients died within six weeks, although only one death was directly attributed to pulmonary aspergillosis. At six monthly follow up, one patient, who initially had a positive Aspergillus culture from bronchial washings and a normal chest radiograph, developed a renal aspergilloma despite the disappearance of Aspergillus sp from the sputum. CONCLUSION Pulmonary aspergillosis is an important clinical problem in patients with AIDS with a CD4 count of less than 50 cells/mm. Furthermore, patients with Aspergillus sp in sputum induction or bronchial washings may develop disseminated disease despite adequate treatment of the primary infection.
Collapse
Affiliation(s)
- J J Keating
- Department of HIV and Genitourinary Medicine, Chelsea and Westminster Hospital, London
| | | | | | | | | | | | | | | |
Collapse
|
28
|
Cartledge JD, Midgley J, Youle M, Gazzard BG. Itraconazole cyclodextrin solution--effective treatment for HIV-related candidosis unresponsive to other azole therapy. J Antimicrob Chemother 1994; 33:1071-3. [PMID: 8089062 DOI: 10.1093/jac/33.5.1071] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
|